RhTNK-tPA is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Yongjun Wang (1), CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. (1) and Beijing Tiantan Hospital (1). Registered phase: Phase 3. Conditions studied include Acute Ischemic Stroke; Large Vessel Occlusion; Anterior Circulation Brain Infarction.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06414499 | Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ (ClinicalTrials.gov ↗) Minor Ischemic Stroke |
Phase 3 | Recruiting |
| NCT07201688 | Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. (ClinicalTrials.gov ↗) Acute Ischemic Stroke |
Phase 3 | Recruiting |
| NCT07748039 | Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (ClinicalTrials.gov ↗) Acute Ischemic Stroke, Large Vessel Occlusion, Anterior Circulation Brain Infarction |
Phase 3 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Ischemic Stroke | 2 |
| Large Vessel Occlusion | 1 |
| Anterior Circulation Brain Infarction | 1 |
| Minor Ischemic Stroke | 1 |
| Lead sponsor | Trials |
|---|---|
| Yongjun Wang | 1 |
| CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | 1 |
| Beijing Tiantan Hospital | 1 |
| Register | RhTNK-tPA trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RhTNK-tPA works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RhTNK-tPA (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.